Increased Risk of Somnolence with the New Dopamine Agonists in Patients with Parkinson’s Disease View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2001-09

AUTHORS

Mahyar Etminan, Ali Samii, Bahi Takkouche, Paula A. Rochon

ABSTRACT

BACKGROUND: Recent case reports and letters have alerted practitioners to the risk of sleep attacks, usually preceded by somnolence, in patients with Parkinson's disease treated with pramipexole and ropinirole. OBJECTIVE: To quantify the risk of somnolence with the new dopamine agonists pramipexole and ropinirole in patients with Parkinson's disease. METHODS: We searched MEDLINE, EMBASE, International Pharmaceutical Abstracts and Cochrane Library, contacted experts and pharmaceutical manufacturers, and manually reviewed all references retrieved to identify possible articles to include. Information on randomisation, blinding, type of treatment and reporting of somnolence were abstracted by 2 independent reviewers. Disagreements were resolved by a third author. ANALYSIS: We made 2 separate analyses. The first analysis compared the risk of somnolence in patients taking either pramipexole or ropinirole to that in patients taking placebo. The second analysis compared the risk of somnolence with these drugs (plus levodopa) versus that with levodopa alone. We calculated pooled relative risk estimates using the random effects model and when no heterogeneity was detected we used the fixed effects model. RESULTS: Four trials were included in the analysis of patients taking pramipexole or ropinirole compared with those taking placebo. The pooled relative risk of somnolence in this analysis was 4.98 [95% confidence interval (CI) 1.79 to 13.89]. Seven trials were included in the analysis of patients taking levodopa and pramipexole or ropinirole compared with those taking levodopa alone. The pooled relative risk was 2.06 (95% CI 1.47 to 2.88). CONCLUSION: Patients with Parkinson's disease using pramipexole or ropinirole are at higher risk of experiencing somnolence relative to patients taking placebo. Patients taking levodopa plus either one of these dopamine agonists are at higher risk than those taking levodopa alone. Clinicians should carefully weigh this risk against the benefit of these agents when prescribing these drugs. More... »

PAGES

863-868

Identifiers

URI

http://scigraph.springernature.com/pub.10.2165/00002018-200124110-00007

DOI

http://dx.doi.org/10.2165/00002018-200124110-00007

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1023820158

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/11665873


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antiparkinson Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Benzothiazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disorders of Excessive Somnolence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dopamine Agonists", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Therapy, Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Indoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Levodopa", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "MEDLINE", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Parkinson Disease", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pramipexole", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Thiazoles", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Toronto", 
          "id": "https://www.grid.ac/institutes/grid.17063.33", 
          "name": [
            "Kunin-Lunenfeld Applied Research Unit, Department of Pharmacy, Baycrest Center for Geriatric Care, 3560 Bathurst Street, M6A 2E1, Toronto, Ontario, Canada", 
            "Department of Clinical Epidemiology, University of Toronto, Toronto, Ontario, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Etminan", 
        "givenName": "Mahyar", 
        "id": "sg:person.0777312127.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0777312127.85"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Washington", 
          "id": "https://www.grid.ac/institutes/grid.34477.33", 
          "name": [
            "Department of Neurology, School of Medicine, University of Washington, Seattle, Washington, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Samii", 
        "givenName": "Ali", 
        "id": "sg:person.0674274205.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0674274205.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Santiago de Compostela", 
          "id": "https://www.grid.ac/institutes/grid.11794.3a", 
          "name": [
            "Department of Preventive Medicine, Faculty of Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Takkouche", 
        "givenName": "Bahi", 
        "id": "sg:person.01161765574.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01161765574.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Toronto", 
          "id": "https://www.grid.ac/institutes/grid.17063.33", 
          "name": [
            "Kunin-Lunenfeld Applied Research Unit, Department of Pharmacy, Baycrest Center for Geriatric Care, 3560 Bathurst Street, M6A 2E1, Toronto, Ontario, Canada", 
            "Departments of Medicine and Public Health Sciences, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada", 
            "Institute for Clinical Evaluative Sciences, Sunnybrook and Women\u2019s College Health Sciences Centre, Toronto, Ontario, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rochon", 
        "givenName": "Paula A.", 
        "id": "sg:person.01005772611.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01005772611.81"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/s0140-6736(00)02119-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000540305"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(00)02118-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001101689"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/mds.870090107", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001244206"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.284.15.1931", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002894278"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1531-8257(200007)15:4<601::aid-mds1003>3.0.co;2-q", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005910454"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.1997.03550020057038", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008045474"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(05)73981-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025015556"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00002826-199619030-00005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025122981"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/mds.870130111", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026535489"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/mds.870130111", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026535489"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm200005183422004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034176125"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/jnnp.66.4.436", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039149672"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/oxfordjournals.aje.a009981", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042600360"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/(sici)1520-6394(2000)11:2<58::aid-da2>3.0.co;2-h", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044748192"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1531-8257(200007)15:4<658::aid-mds1009>3.0.co;2-n", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048708797"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/archneur.55.9.1211", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1054116661"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.278.2.125", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1054161656"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.49.2.393", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064375188"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.49.2.393", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064375188"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.49.2.393", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064375188"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.49.3.724", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064375305"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.49.3.724", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064375305"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.49.3.724", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064375305"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.51.4.1057", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064376768"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.51.4.1057", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064376768"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.51.4.1057", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064376768"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.52.9.1908", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064377530"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.52.9.1908", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064377530"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.52.9.1908", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064377530"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.53.3.573", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064377675"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.53.3.573", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064377675"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.53.3.573", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064377675"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082880595", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082935991", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083258004", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083274678", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2001-09", 
    "datePublishedReg": "2001-09-01", 
    "description": "BACKGROUND: Recent case reports and letters have alerted practitioners to the risk of sleep attacks, usually preceded by somnolence, in patients with Parkinson's disease treated with pramipexole and ropinirole.\nOBJECTIVE: To quantify the risk of somnolence with the new dopamine agonists pramipexole and ropinirole in patients with Parkinson's disease.\nMETHODS: We searched MEDLINE, EMBASE, International Pharmaceutical Abstracts and Cochrane Library, contacted experts and pharmaceutical manufacturers, and manually reviewed all references retrieved to identify possible articles to include. Information on randomisation, blinding, type of treatment and reporting of somnolence were abstracted by 2 independent reviewers. Disagreements were resolved by a third author.\nANALYSIS: We made 2 separate analyses. The first analysis compared the risk of somnolence in patients taking either pramipexole or ropinirole to that in patients taking placebo. The second analysis compared the risk of somnolence with these drugs (plus levodopa) versus that with levodopa alone. We calculated pooled relative risk estimates using the random effects model and when no heterogeneity was detected we used the fixed effects model.\nRESULTS: Four trials were included in the analysis of patients taking pramipexole or ropinirole compared with those taking placebo. The pooled relative risk of somnolence in this analysis was 4.98 [95% confidence interval (CI) 1.79 to 13.89]. Seven trials were included in the analysis of patients taking levodopa and pramipexole or ropinirole compared with those taking levodopa alone. The pooled relative risk was 2.06 (95% CI 1.47 to 2.88).\nCONCLUSION: Patients with Parkinson's disease using pramipexole or ropinirole are at higher risk of experiencing somnolence relative to patients taking placebo. Patients taking levodopa plus either one of these dopamine agonists are at higher risk than those taking levodopa alone. Clinicians should carefully weigh this risk against the benefit of these agents when prescribing these drugs.", 
    "genre": "research_article", 
    "id": "sg:pub.10.2165/00002018-200124110-00007", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1096281", 
        "issn": [
          "0114-5916", 
          "1179-1942"
        ], 
        "name": "Drug Safety", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "11", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "24"
      }
    ], 
    "name": "Increased Risk of Somnolence with the New Dopamine Agonists in Patients with Parkinson\u2019s Disease", 
    "pagination": "863-868", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "717bbf921409405730d801ac11c5854860b117d3da07c50c380c56c140f201ef"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "11665873"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9002928"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.2165/00002018-200124110-00007"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1023820158"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.2165/00002018-200124110-00007", 
      "https://app.dimensions.ai/details/publication/pub.1023820158"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T12:39", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000363_0000000363/records_70046_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.2165/00002018-200124110-00007"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/00002018-200124110-00007'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/00002018-200124110-00007'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/00002018-200124110-00007'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/00002018-200124110-00007'


 

This table displays all metadata directly associated to this object as RDF triples.

226 TRIPLES      21 PREDICATES      68 URIs      35 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.2165/00002018-200124110-00007 schema:about N02143510bcdd4f13a08cfaea3311ef31
2 N048e1ba1f743433dbbf1810f7ead0aa1
3 N13fe7ff754ab4b53a265d5cc18cabe4c
4 N37e8c416c7f149e4b61673b7a3800ff9
5 N3d16be4859344a2aa7026a275cc09698
6 N47f5551fe68d4b0794c9fa537cf9da8b
7 N4bc83f9b326241c59699f81d96dcb910
8 N577a5ba1243547d29d9d301df2c96830
9 N71c589e18fa94c25a8222c85037aea3f
10 N8d5932759aa648c8904beba96c8cbb2a
11 N9b0b953752b145f2a4fe81abeb7c1194
12 Na4cad1c4eaa24cbda4378f63878e01ba
13 Na4d53679dc7c44b3a9ba230edc66263a
14 Nd2dd34a0d2494ea09b24b7b4b3ce42f4
15 anzsrc-for:11
16 anzsrc-for:1117
17 schema:author Nc23b74d461674c6fab388ef55f7fd99b
18 schema:citation https://app.dimensions.ai/details/publication/pub.1082880595
19 https://app.dimensions.ai/details/publication/pub.1082935991
20 https://app.dimensions.ai/details/publication/pub.1083258004
21 https://app.dimensions.ai/details/publication/pub.1083274678
22 https://doi.org/10.1001/archneur.55.9.1211
23 https://doi.org/10.1001/jama.1997.03550020057038
24 https://doi.org/10.1001/jama.278.2.125
25 https://doi.org/10.1001/jama.284.15.1931
26 https://doi.org/10.1002/(sici)1520-6394(2000)11:2<58::aid-da2>3.0.co;2-h
27 https://doi.org/10.1002/1531-8257(200007)15:4<601::aid-mds1003>3.0.co;2-q
28 https://doi.org/10.1002/1531-8257(200007)15:4<658::aid-mds1009>3.0.co;2-n
29 https://doi.org/10.1002/mds.870090107
30 https://doi.org/10.1002/mds.870130111
31 https://doi.org/10.1016/s0140-6736(00)02118-8
32 https://doi.org/10.1016/s0140-6736(00)02119-x
33 https://doi.org/10.1016/s0140-6736(05)73981-7
34 https://doi.org/10.1056/nejm200005183422004
35 https://doi.org/10.1093/oxfordjournals.aje.a009981
36 https://doi.org/10.1097/00002826-199619030-00005
37 https://doi.org/10.1136/jnnp.66.4.436
38 https://doi.org/10.1212/wnl.49.2.393
39 https://doi.org/10.1212/wnl.49.3.724
40 https://doi.org/10.1212/wnl.51.4.1057
41 https://doi.org/10.1212/wnl.52.9.1908
42 https://doi.org/10.1212/wnl.53.3.573
43 schema:datePublished 2001-09
44 schema:datePublishedReg 2001-09-01
45 schema:description BACKGROUND: Recent case reports and letters have alerted practitioners to the risk of sleep attacks, usually preceded by somnolence, in patients with Parkinson's disease treated with pramipexole and ropinirole. OBJECTIVE: To quantify the risk of somnolence with the new dopamine agonists pramipexole and ropinirole in patients with Parkinson's disease. METHODS: We searched MEDLINE, EMBASE, International Pharmaceutical Abstracts and Cochrane Library, contacted experts and pharmaceutical manufacturers, and manually reviewed all references retrieved to identify possible articles to include. Information on randomisation, blinding, type of treatment and reporting of somnolence were abstracted by 2 independent reviewers. Disagreements were resolved by a third author. ANALYSIS: We made 2 separate analyses. The first analysis compared the risk of somnolence in patients taking either pramipexole or ropinirole to that in patients taking placebo. The second analysis compared the risk of somnolence with these drugs (plus levodopa) versus that with levodopa alone. We calculated pooled relative risk estimates using the random effects model and when no heterogeneity was detected we used the fixed effects model. RESULTS: Four trials were included in the analysis of patients taking pramipexole or ropinirole compared with those taking placebo. The pooled relative risk of somnolence in this analysis was 4.98 [95% confidence interval (CI) 1.79 to 13.89]. Seven trials were included in the analysis of patients taking levodopa and pramipexole or ropinirole compared with those taking levodopa alone. The pooled relative risk was 2.06 (95% CI 1.47 to 2.88). CONCLUSION: Patients with Parkinson's disease using pramipexole or ropinirole are at higher risk of experiencing somnolence relative to patients taking placebo. Patients taking levodopa plus either one of these dopamine agonists are at higher risk than those taking levodopa alone. Clinicians should carefully weigh this risk against the benefit of these agents when prescribing these drugs.
46 schema:genre research_article
47 schema:inLanguage en
48 schema:isAccessibleForFree false
49 schema:isPartOf N4eb61ea9a73b405f9f4638510df0c0a7
50 Ncebc79edef8341b79fd65b1d00f11a61
51 sg:journal.1096281
52 schema:name Increased Risk of Somnolence with the New Dopamine Agonists in Patients with Parkinson’s Disease
53 schema:pagination 863-868
54 schema:productId N45dcb120d52d47188c3035e00665e0b3
55 N8d10733882e74aa99ae655cd33f80909
56 Nbd61e40b0ae24c6eb0277c95832accf8
57 Nccaf49393ab04116b2134b5a026bd3c6
58 Nd30f7e3bbbc14906b71c9fe86e668558
59 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023820158
60 https://doi.org/10.2165/00002018-200124110-00007
61 schema:sdDatePublished 2019-04-11T12:39
62 schema:sdLicense https://scigraph.springernature.com/explorer/license/
63 schema:sdPublisher N995b94f1b8d2400d81695c490473d1fa
64 schema:url http://link.springer.com/10.2165/00002018-200124110-00007
65 sgo:license sg:explorer/license/
66 sgo:sdDataset articles
67 rdf:type schema:ScholarlyArticle
68 N02143510bcdd4f13a08cfaea3311ef31 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
69 schema:name Benzothiazoles
70 rdf:type schema:DefinedTerm
71 N048e1ba1f743433dbbf1810f7ead0aa1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
72 schema:name Thiazoles
73 rdf:type schema:DefinedTerm
74 N13fe7ff754ab4b53a265d5cc18cabe4c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
75 schema:name Levodopa
76 rdf:type schema:DefinedTerm
77 N37e8c416c7f149e4b61673b7a3800ff9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Disorders of Excessive Somnolence
79 rdf:type schema:DefinedTerm
80 N3d16be4859344a2aa7026a275cc09698 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Parkinson Disease
82 rdf:type schema:DefinedTerm
83 N45dcb120d52d47188c3035e00665e0b3 schema:name doi
84 schema:value 10.2165/00002018-200124110-00007
85 rdf:type schema:PropertyValue
86 N47f5551fe68d4b0794c9fa537cf9da8b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name MEDLINE
88 rdf:type schema:DefinedTerm
89 N4bc83f9b326241c59699f81d96dcb910 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Antiparkinson Agents
91 rdf:type schema:DefinedTerm
92 N4eb61ea9a73b405f9f4638510df0c0a7 schema:issueNumber 11
93 rdf:type schema:PublicationIssue
94 N577a5ba1243547d29d9d301df2c96830 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Randomized Controlled Trials as Topic
96 rdf:type schema:DefinedTerm
97 N684efbd09a5a429ab185edc3ebba64e1 rdf:first sg:person.01005772611.81
98 rdf:rest rdf:nil
99 N70ec9287b3a248c6888defc0fc9b76f3 rdf:first sg:person.0674274205.79
100 rdf:rest N7abdef8e7fac45b68bf8c76b4f243179
101 N71c589e18fa94c25a8222c85037aea3f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Pramipexole
103 rdf:type schema:DefinedTerm
104 N7abdef8e7fac45b68bf8c76b4f243179 rdf:first sg:person.01161765574.42
105 rdf:rest N684efbd09a5a429ab185edc3ebba64e1
106 N8d10733882e74aa99ae655cd33f80909 schema:name dimensions_id
107 schema:value pub.1023820158
108 rdf:type schema:PropertyValue
109 N8d5932759aa648c8904beba96c8cbb2a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Drug Therapy, Combination
111 rdf:type schema:DefinedTerm
112 N995b94f1b8d2400d81695c490473d1fa schema:name Springer Nature - SN SciGraph project
113 rdf:type schema:Organization
114 N9b0b953752b145f2a4fe81abeb7c1194 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Dopamine Agonists
116 rdf:type schema:DefinedTerm
117 Na4cad1c4eaa24cbda4378f63878e01ba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Indoles
119 rdf:type schema:DefinedTerm
120 Na4d53679dc7c44b3a9ba230edc66263a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Risk Factors
122 rdf:type schema:DefinedTerm
123 Nbd61e40b0ae24c6eb0277c95832accf8 schema:name nlm_unique_id
124 schema:value 9002928
125 rdf:type schema:PropertyValue
126 Nc23b74d461674c6fab388ef55f7fd99b rdf:first sg:person.0777312127.85
127 rdf:rest N70ec9287b3a248c6888defc0fc9b76f3
128 Nccaf49393ab04116b2134b5a026bd3c6 schema:name pubmed_id
129 schema:value 11665873
130 rdf:type schema:PropertyValue
131 Ncebc79edef8341b79fd65b1d00f11a61 schema:volumeNumber 24
132 rdf:type schema:PublicationVolume
133 Nd2dd34a0d2494ea09b24b7b4b3ce42f4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Humans
135 rdf:type schema:DefinedTerm
136 Nd30f7e3bbbc14906b71c9fe86e668558 schema:name readcube_id
137 schema:value 717bbf921409405730d801ac11c5854860b117d3da07c50c380c56c140f201ef
138 rdf:type schema:PropertyValue
139 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
140 schema:name Medical and Health Sciences
141 rdf:type schema:DefinedTerm
142 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
143 schema:name Public Health and Health Services
144 rdf:type schema:DefinedTerm
145 sg:journal.1096281 schema:issn 0114-5916
146 1179-1942
147 schema:name Drug Safety
148 rdf:type schema:Periodical
149 sg:person.01005772611.81 schema:affiliation https://www.grid.ac/institutes/grid.17063.33
150 schema:familyName Rochon
151 schema:givenName Paula A.
152 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01005772611.81
153 rdf:type schema:Person
154 sg:person.01161765574.42 schema:affiliation https://www.grid.ac/institutes/grid.11794.3a
155 schema:familyName Takkouche
156 schema:givenName Bahi
157 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01161765574.42
158 rdf:type schema:Person
159 sg:person.0674274205.79 schema:affiliation https://www.grid.ac/institutes/grid.34477.33
160 schema:familyName Samii
161 schema:givenName Ali
162 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0674274205.79
163 rdf:type schema:Person
164 sg:person.0777312127.85 schema:affiliation https://www.grid.ac/institutes/grid.17063.33
165 schema:familyName Etminan
166 schema:givenName Mahyar
167 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0777312127.85
168 rdf:type schema:Person
169 https://app.dimensions.ai/details/publication/pub.1082880595 schema:CreativeWork
170 https://app.dimensions.ai/details/publication/pub.1082935991 schema:CreativeWork
171 https://app.dimensions.ai/details/publication/pub.1083258004 schema:CreativeWork
172 https://app.dimensions.ai/details/publication/pub.1083274678 schema:CreativeWork
173 https://doi.org/10.1001/archneur.55.9.1211 schema:sameAs https://app.dimensions.ai/details/publication/pub.1054116661
174 rdf:type schema:CreativeWork
175 https://doi.org/10.1001/jama.1997.03550020057038 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008045474
176 rdf:type schema:CreativeWork
177 https://doi.org/10.1001/jama.278.2.125 schema:sameAs https://app.dimensions.ai/details/publication/pub.1054161656
178 rdf:type schema:CreativeWork
179 https://doi.org/10.1001/jama.284.15.1931 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002894278
180 rdf:type schema:CreativeWork
181 https://doi.org/10.1002/(sici)1520-6394(2000)11:2<58::aid-da2>3.0.co;2-h schema:sameAs https://app.dimensions.ai/details/publication/pub.1044748192
182 rdf:type schema:CreativeWork
183 https://doi.org/10.1002/1531-8257(200007)15:4<601::aid-mds1003>3.0.co;2-q schema:sameAs https://app.dimensions.ai/details/publication/pub.1005910454
184 rdf:type schema:CreativeWork
185 https://doi.org/10.1002/1531-8257(200007)15:4<658::aid-mds1009>3.0.co;2-n schema:sameAs https://app.dimensions.ai/details/publication/pub.1048708797
186 rdf:type schema:CreativeWork
187 https://doi.org/10.1002/mds.870090107 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001244206
188 rdf:type schema:CreativeWork
189 https://doi.org/10.1002/mds.870130111 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026535489
190 rdf:type schema:CreativeWork
191 https://doi.org/10.1016/s0140-6736(00)02118-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001101689
192 rdf:type schema:CreativeWork
193 https://doi.org/10.1016/s0140-6736(00)02119-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1000540305
194 rdf:type schema:CreativeWork
195 https://doi.org/10.1016/s0140-6736(05)73981-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025015556
196 rdf:type schema:CreativeWork
197 https://doi.org/10.1056/nejm200005183422004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034176125
198 rdf:type schema:CreativeWork
199 https://doi.org/10.1093/oxfordjournals.aje.a009981 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042600360
200 rdf:type schema:CreativeWork
201 https://doi.org/10.1097/00002826-199619030-00005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025122981
202 rdf:type schema:CreativeWork
203 https://doi.org/10.1136/jnnp.66.4.436 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039149672
204 rdf:type schema:CreativeWork
205 https://doi.org/10.1212/wnl.49.2.393 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064375188
206 rdf:type schema:CreativeWork
207 https://doi.org/10.1212/wnl.49.3.724 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064375305
208 rdf:type schema:CreativeWork
209 https://doi.org/10.1212/wnl.51.4.1057 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064376768
210 rdf:type schema:CreativeWork
211 https://doi.org/10.1212/wnl.52.9.1908 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064377530
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1212/wnl.53.3.573 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064377675
214 rdf:type schema:CreativeWork
215 https://www.grid.ac/institutes/grid.11794.3a schema:alternateName University of Santiago de Compostela
216 schema:name Department of Preventive Medicine, Faculty of Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain
217 rdf:type schema:Organization
218 https://www.grid.ac/institutes/grid.17063.33 schema:alternateName University of Toronto
219 schema:name Department of Clinical Epidemiology, University of Toronto, Toronto, Ontario, Canada
220 Departments of Medicine and Public Health Sciences, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
221 Institute for Clinical Evaluative Sciences, Sunnybrook and Women’s College Health Sciences Centre, Toronto, Ontario, Canada
222 Kunin-Lunenfeld Applied Research Unit, Department of Pharmacy, Baycrest Center for Geriatric Care, 3560 Bathurst Street, M6A 2E1, Toronto, Ontario, Canada
223 rdf:type schema:Organization
224 https://www.grid.ac/institutes/grid.34477.33 schema:alternateName University of Washington
225 schema:name Department of Neurology, School of Medicine, University of Washington, Seattle, Washington, USA
226 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...